NIKKEI 225
38,460.08 +907.92 (+2.42%) HANG SENG
17,201.27 +372.34 (+2.21%) CRUDE OIL
82.77 -0.59 (-0.71%) GOLD FUTURES
2,327.90 -14.20 (-0.61%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,374.62 -1,851.04 (-3.48%)
Moderna, Inc. (0A45.IL)
| Previous close | 107.07 |
| Open | 108.00 |
| Bid | 104.22 x N/A |
| Ask | 109.56 x N/A |
| Day's range | 106.71 - 111.10 |
| 52-week range | 62.55 - 142.32 |
| Volume | |
| Avg. volume | 17,809 |
| Market cap | 51.969B |
| Beta (5Y monthly) | 1.64 |
| PE ratio (TTM) | 39.88 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Reuters
Pfizer vs Moderna battle over COVID vaccine patents begins in UK
Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday. Pfizer and its German partner BioNTech sued Moderna at London's High Court in September 2022, seeking to revoke patents held by Moderna, which hit back days later alleging its patents had been infringed. Moderna says Pfizer and BioNTech copied mRNA advances it had pioneered and patented well before the COVID-19 pandemic began in late 2019.
- CityAM
This may hurt: English High Court set for Moderna and Pfizer/BioNTech Covid battle starting today
The English part of a global dispute billion dollar legal case involving big pharma giants Modern, Pfizer and BioNTech over Covid patents, kicks off today.
- Simply Wall St.
Insiders At Moderna Sold US$3.3m In Stock, Alluding To Potential Weakness
In the last year, many Moderna, Inc. ( NASDAQ:MRNA ) insiders sold a substantial stake in the company which may have...
